Ann: Quarterly Activities Report and Appendix 4C, page-10

Understand the frustrations about the further NMPA delay, and the revenue is definitely pretty flat at around $1.4m USD.

But at least the Total Expenses ($2,093k) and Nett Cash Outflows ($689) have dropped significantly again. That continues the trend of them tightening their belts.

They need that hospital deal (500 x beds) to be done in the US fairly smartly, they need to finalise the FCL deal, and it would also be great to get an update about what is happening with the 10 x hospital trials in the UK?